S

Sansure Biotech Inc
SSE:688289

Watchlist Manager
Sansure Biotech Inc
SSE:688289
Watchlist
Price: 17.24 CNY 0.64% Market Closed
Market Cap: ¥10B

Sansure Biotech Inc
PP&E Gross

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Sansure Biotech Inc
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
S
Sansure Biotech Inc
SSE:688289
PP&E Gross
¥1.2B
CAGR 3-Years
30%
CAGR 5-Years
46%
CAGR 10-Years
N/A
S
Shanghai Conant Optical Co Ltd
HKEX:2276
PP&E Gross
¥411.3m
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Autobio Diagnostics Co Ltd
SSE:603658
PP&E Gross
¥3.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
PP&E Gross
¥5B
CAGR 3-Years
29%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
PP&E Gross
¥1.7B
CAGR 3-Years
13%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Intco Medical Technology Co Ltd
SZSE:300677
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sansure Biotech Inc
Glance View

Market Cap
10B CNY
Industry
Health Care

Nestled in the bustling hub of China's life sciences innovation, Sansure Biotech Inc. has emerged as a pivotal player in the biotechnology landscape. Founded with a vision to harness cutting-edge technology for health diagnostics, the company has developed a comprehensive suite of diagnostic products and solutions. At its core, Sansure specializes in the research, development, and commercialization of in-vitro diagnostic reagents and instruments. By leveraging its proprietary technologies, the company addresses pressing global health challenges with precision diagnostics that span infectious diseases, oncology, and genetic testing, among others. Its portfolio encompasses both equipment and consumables, offering end-to-end solutions that enable healthcare providers to deliver accurate and timely diagnoses. Sansure's business model is intricately woven into the fabric of both innovation and distribution. The company thrives by consistently innovating its product line to keep pace with global health demands while optimizing its production processes for scale and efficiency. Revenue streams flow from the sale of its diagnostic kits and instruments, which are widely adopted in hospitals, clinics, and laboratories. Collaborations with research institutions and healthcare bodies have further cemented its status as a trusted partner in public health. Through strategic partnerships and an expanding international footprint, Sansure has built a robust distribution network that ensures its technologies are accessible to a diverse market, thus driving its financial growth and solidifying its standing in the biotech industry.

Intrinsic Value
21.19 CNY
Undervaluation 19%
Intrinsic Value
Price ¥17.24
S

See Also

What is Sansure Biotech Inc's PP&E Gross?
PP&E Gross
1.2B CNY

Based on the financial report for Dec 31, 2024, Sansure Biotech Inc's PP&E Gross amounts to 1.2B CNY.

What is Sansure Biotech Inc's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
46%

Over the last year, the PP&E Gross growth was 10%. The average annual PP&E Gross growth rates for Sansure Biotech Inc have been 30% over the past three years , 46% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett